BIOMAT Database Logo BIOMAT Database Logo

Combination chemotherapy comprising 5-fluorouracil, leucovorin, etoposide, and cis-diamminedichloroplatinum for the treatment of advanced gastric cancer. 2002

Fumiro Mochizuki, and Masashi Fujii, and Yuichi Kasakura, and Motoo Yamagata, and Mitsugu Kochi, and Kazuhiko Wakabayashi, and Noriaki Kanamori, and Tadatoshi Takayama
Third Department of Surgery, Nihon University School of Medicine, 30-1 Oyaguchikami-machi, Itabashi-ku, Tokyo 173-8610, Japan. fumiro@jcom.home.ne.jp

OBJECTIVE The FLEP regimen (5-FU, LV, ETP, and CDDP) has been recommended as a combination chemotherapy to control advanced and recurrent gastric cancer. We performed a phase II study of this regimen in 49 patients with advanced gastric cancer. METHODS The treatment regimen consisted of: 5-FU at 370 mg/m(2) (days 1-5, i.v. 24 h); LV at a dose of 30 mg (days 1-5, i.v. bolus); and ETP and CDDP each at 70 mg/m(2) (days 7 and 21, i.a. 2 h), which was repeated every five weeks. RESULTS The overall response rate was 40.8% (20/49 patients) and the median survival time was 12.6 months (range 1.1-41.8). The adverse events were Grade 3/4 leukocytopenia (16.3%), Grade 3/4 thrombocytopenia (8.2%), Grade 3 nausea and/or vomiting (4.1%), and Grade 3 stomatitis (2.0%). CONCLUSIONS Based on the encouraging response rate and prognosis, we recommend applying the FLEP regimen to patients with primary advanced gastric cancer.

UI MeSH Term Description Entries
D007970 Leukopenia A decrease in the number of LEUKOCYTES in a blood sample below the normal range (LEUKOCYTE COUNT less than 4000). Leukocytopenia,Leukocytopenias,Leukopenias
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D002945 Cisplatin An inorganic and water-soluble platinum complex. After undergoing hydrolysis, it reacts with DNA to produce both intra and interstrand crosslinks. These crosslinks appear to impair replication and transcription of DNA. The cytotoxicity of cisplatin correlates with cellular arrest in the G2 phase of the cell cycle. Platinum Diamminodichloride,cis-Diamminedichloroplatinum(II),cis-Dichlorodiammineplatinum(II),Biocisplatinum,Dichlorodiammineplatinum,NSC-119875,Platidiam,Platino,Platinol,cis-Diamminedichloroplatinum,cis-Platinum,Diamminodichloride, Platinum,cis Diamminedichloroplatinum,cis Platinum
D002955 Leucovorin The active metabolite of FOLIC ACID. Leucovorin is used principally as an antidote to FOLIC ACID ANTAGONISTS. Calcium Leucovorin,Citrovorum Factor,Folinic Acid,N(5)-Formyltetrahydrofolate,5-Formyltetrahydrofolate,5-Formyltetrahydropteroylglutamate,Calcium Folinate,Folinic Acid-SF,Leucovorin, (D)-Isomer,Leucovorin, (DL)-Isomer,Leucovorin, (R)-Isomer,Leucovorin, Calcium (1:1) Salt,Leucovorin, Calcium (1:1) Salt, (DL)-Isomer,Leucovorin, Calcium (1:1) Salt, Pentahydrate,Leucovorin, Monosodium Salt,Leukovorin,Leukovorum,Wellcovorin,5 Formyltetrahydrofolate,5 Formyltetrahydropteroylglutamate,Acid, Folinic,Factor, Citrovorum,Folinate, Calcium,Folinic Acid SF,Leucovorin, Calcium,Monosodium Salt Leucovorin
D005047 Etoposide A semisynthetic derivative of PODOPHYLLOTOXIN that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle. Demethyl Epipodophyllotoxin Ethylidine Glucoside,Celltop,Eposide,Eposin,Eto-GRY,Etomedac,Etopos,Etoposide Pierre Fabre,Etoposide Teva,Etoposide, (5S)-Isomer,Etoposide, (5a alpha)-Isomer,Etoposide, (5a alpha,9 alpha)-Isomer,Etoposide, alpha-D-Glucopyranosyl Isomer,Etoposido Ferrer Farma,Exitop,Lastet,NSC-141540,Onkoposid,Riboposid,Toposar,VP 16-213,VP-16,Vepesid,Vépéside-Sandoz,Eto GRY,Etoposide, alpha D Glucopyranosyl Isomer,NSC 141540,NSC141540,Teva, Etoposide,VP 16,VP 16 213,VP 16213,VP16,Vépéside Sandoz,alpha-D-Glucopyranosyl Isomer Etoposide
D005260 Female Females
D005472 Fluorouracil A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid. 5-FU,5-FU Lederle,5-FU Medac,5-Fluorouracil,5-Fluorouracil-Biosyn,5-HU Hexal,5FU,Adrucil,Carac,Efudex,Efudix,Fluoro-Uracile ICN,Fluoroplex,Fluorouracil Mononitrate,Fluorouracil Monopotassium Salt,Fluorouracil Monosodium Salt,Fluorouracil Potassium Salt,Fluorouracil-GRY,Fluorouracile Dakota,Fluorouracilo Ferrer Far,Fluoruracil,Fluracedyl,Flurodex,Haemato-FU,Neofluor,Onkofluor,Ribofluor,5 FU Lederle,5 FU Medac,5 Fluorouracil,5 Fluorouracil Biosyn,5 HU Hexal,Dakota, Fluorouracile,Fluoro Uracile ICN,Fluorouracil GRY,Haemato FU
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

Fumiro Mochizuki, and Masashi Fujii, and Yuichi Kasakura, and Motoo Yamagata, and Mitsugu Kochi, and Kazuhiko Wakabayashi, and Noriaki Kanamori, and Tadatoshi Takayama
Etoposide, leucovorin, 5-fluorouracil (ELF) combination chemotherapy for advanced gastric cancer: experience with two treatment schedules incorporating intravenous or oral etoposide.
January 1994, Annals of oncology : official journal of the European Society for Medical Oncology,
Fumiro Mochizuki, and Masashi Fujii, and Yuichi Kasakura, and Motoo Yamagata, and Mitsugu Kochi, and Kazuhiko Wakabayashi, and Noriaki Kanamori, and Tadatoshi Takayama
[Clinical analysis of adjuvant chemotherapy using 5-fluorouracil, leucovorin and cis-diamminedichloroplatinum for patients with advanced and recurrent gastric cancer].
February 1997, Gan to kagaku ryoho. Cancer & chemotherapy,
Fumiro Mochizuki, and Masashi Fujii, and Yuichi Kasakura, and Motoo Yamagata, and Mitsugu Kochi, and Kazuhiko Wakabayashi, and Noriaki Kanamori, and Tadatoshi Takayama
FLEP (5-fluorouracil, leucovorin, etoposide, cisplatin) in advanced gastric cancer.
January 1994, European journal of cancer (Oxford, England : 1990),
Fumiro Mochizuki, and Masashi Fujii, and Yuichi Kasakura, and Motoo Yamagata, and Mitsugu Kochi, and Kazuhiko Wakabayashi, and Noriaki Kanamori, and Tadatoshi Takayama
Weekly etoposide, epirubicin, cisplatin, 5-fluorouracil and leucovorin: an effective chemotherapy in advanced gastric cancer.
June 1998, British journal of cancer,
Fumiro Mochizuki, and Masashi Fujii, and Yuichi Kasakura, and Motoo Yamagata, and Mitsugu Kochi, and Kazuhiko Wakabayashi, and Noriaki Kanamori, and Tadatoshi Takayama
Treatment of advanced gastric cancer with a modified regimen of etoposide/leucovorin/5-fluorouracil.
January 1996, Cancer investigation,
Fumiro Mochizuki, and Masashi Fujii, and Yuichi Kasakura, and Motoo Yamagata, and Mitsugu Kochi, and Kazuhiko Wakabayashi, and Noriaki Kanamori, and Tadatoshi Takayama
Treatment of elderly advanced gastric cancer patients with 5-fluorouracil and leucovorin combination.
June 1992, Journal of chemotherapy (Florence, Italy),
Fumiro Mochizuki, and Masashi Fujii, and Yuichi Kasakura, and Motoo Yamagata, and Mitsugu Kochi, and Kazuhiko Wakabayashi, and Noriaki Kanamori, and Tadatoshi Takayama
[Combination chemotherapy of 5-fluorouracil (5-FU), adriamycin (ADM), cis-diamminedichloroplatinum (II) (CDDP) and mitomycin C (MMC) (FAP.MMC) in advanced gastric cancer].
January 1988, Gan to kagaku ryoho. Cancer & chemotherapy,
Fumiro Mochizuki, and Masashi Fujii, and Yuichi Kasakura, and Motoo Yamagata, and Mitsugu Kochi, and Kazuhiko Wakabayashi, and Noriaki Kanamori, and Tadatoshi Takayama
Phase II study of the etoposide, leucovorin and fluorouracil combination for patients with advanced gastric cancer unsuitable for aggressive chemotherapy.
January 1995, Oncology,
Fumiro Mochizuki, and Masashi Fujii, and Yuichi Kasakura, and Motoo Yamagata, and Mitsugu Kochi, and Kazuhiko Wakabayashi, and Noriaki Kanamori, and Tadatoshi Takayama
Paclitaxel, 5-fluorouracil, and leucovorin combination chemotherapy as first-line treatment in patients with advanced gastric cancer.
March 2019, Anti-cancer drugs,
Fumiro Mochizuki, and Masashi Fujii, and Yuichi Kasakura, and Motoo Yamagata, and Mitsugu Kochi, and Kazuhiko Wakabayashi, and Noriaki Kanamori, and Tadatoshi Takayama
Oxaliplatin, 5-fluorouracil and leucovorin (FOLFOX-4) combination chemotherapy as a salvage treatment in advanced gastric cancer.
March 2010, Cancer research and treatment,
Copied contents to your clipboard!